Abstract 170P
Background
The interaction between gastric cancer (GC) tumor cells and tumor microenvironment could impact on the response to conventional chemotherapies (CT). The aim of this study was to obtain a wide transcriptomic profile with spatial resolution of tissue samples from locally advanced GC patients (pts) who present extremely different response to neoadjuvant CT (NCT).
Methods
Nanostring GeoMx Digital Spatial Profiler (DSP) was performed on pre-therapy biopsies and matched surgical specimens from 6 patients who received NCT. Three pts reached a complete pathological response (CRs), the remaining do not respond (NRs). Regions of interest were visualized on FFPE sections based on immunofluorescent staining for nuclear (DNASyto13), tumor (Pan-cytokeratin) and immune cell (CD45) compartments. Expression levels of more 1,800 genes were evaluated by using the Cancer Transcriptome Atlas (CTA) panel. Transcripts counts were generated using NextSeq 550 instrument (Illumina) and analysed by DSP analysis suite (Nanostring). Effector memory T cells were analysed by immunoistochemistry using CD45RO antibody.
Results
Cells in the tumor compartment of CRs presented an enrichment of deregulated pathways involved in extracellular matrix (ECM) organization and degradation, whereas key pathways involved in cell junction organization, interferon signaling and cell-cell communication were upregulated in NRs. Higher levels of intratumoral CD45RO staining was observed in CRs. A high number of pathways, mainly related to the ECM remodelling and cell surface interaction, as for tumoral cells, resulted upregulated in immune compartment of CRs. Conversely, lymphocytes in NRs were characterized by enrichment in genes involved in the signaling by B cell receptor and generation of second messenger molecules.
Conclusions
A comprehensive characterization of the expression profile of tumor and immune cells showed the contribution of both compartments in the chemosensitivity, mainly through the regulation of ECM organization and remodeling. DSP-based analyses will help to decipher the different responses of GC patients to chemotherapy, enabling the identification of potential biomarker signatures.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \"Dino Amadori\".
Funding
Italian Ministry of Health within the ERAPerMed Project GRAMMY (ERP-2019-23671108; GRAMMY, 2019-275).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
71P - When neighbors play a role: The importance of interacting proteins in the tumorigenic effect of cancer driver genes
Presenter: Margarida Carrolo
Session: Cocktail & Poster Display session
Resources:
Abstract
72P - SNCG promotes the malignant progression of hepatocellular carcinoma by activation EGFR signaling and recycling
Presenter: Yue Chen
Session: Cocktail & Poster Display session
Resources:
Abstract
73P - TROP2 amplification is highly present in dedifferentiated liposarcoma: Data from the Cancer Genome Atlas (TCGA) in soft tissue sarcoma
Presenter: Sarah Orlando
Session: Cocktail & Poster Display session
Resources:
Abstract
74P - The influence of genetic phenotype on prognosis of osteosarcoma
Presenter: Nasirov Kamalovich
Session: Cocktail & Poster Display session
Resources:
Abstract
76P - Immune engager compounds screening using CRC patient-derived organoids
Presenter: Claudia Maria A. Pinna
Session: Cocktail & Poster Display session
Resources:
Abstract
77P - Elucidating molecularly stratified single agent, and combination, therapeutic strategies targeting MCL1 for lethal prostate cancer
Presenter: Juan Jiménez-Vacas
Session: Cocktail & Poster Display session
Resources:
Abstract
78P - Exploring ecDNA heterogeneity and evolution in non-small cell lung cancer
Presenter: Jeanette Kittel
Session: Cocktail & Poster Display session
Resources:
Abstract
79P - Targeting galectin-9 in BRCA mutant breast cancer
Presenter: Chun Yan So
Session: Cocktail & Poster Display session
Resources:
Abstract
80P - Suppression of glioblastoma progression by FDA-approved central nervous system-accumulating drugs via autophagy modulation and ER stress-induced apoptosis
Presenter: Smita Dey
Session: Cocktail & Poster Display session
Resources:
Abstract
81P - Evaluating the effect of lenvatinib-resistance in hepatocellular carcinoma cells and in lenvatinib-resistant patient-derived PBMCs
Presenter: Luisa Amato
Session: Cocktail & Poster Display session
Resources:
Abstract